TrialAnti-cancer drugs2025
A phase II study of anlotinib as first-line maintenance therapy for advanced ovarian cancer.
Siyuan Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
TrialAnti-cancer drugs2025
Siyuan Li et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.